Lunsumio

Hong Kong, September 17, 2026 Akeso, Inc. has announced that its investigational AK158D1, a next-generation EGFR/TROP2 bispecific antibody-drug conjugate...

Basel, Switzerland, September 17, 2026 Roche has announced positive results from the Phase III CELESTIMO study, showing that a...

SOUTH SAN FRANCISCO, Calif. — September 16, 2026 Genentech announced that the Phase III CELESTIMO study of Lunsumio® (mosunetuzumab-axgb)...

WATERTOWN, Mass., September 2, 2026 Treeline Biosciences, Inc. announced a clinical trial collaboration and supply agreement with Roche to...

SOUTH SAN FRANCISCO, Calif., May 18, 2026 Genentech, a member of the Roche Group, announced that it will present...